These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30402450)

  • 1. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.
    Drazilova S; Janicko M; Skladany L; Kristian P; Oltman M; Szantova M; Krkoska D; Mazuchova E; Piesecka L; Vahalova V; Rac M; Schreter I; Virag L; Koller T; Liptakova A; Ondrasova M; Jarcuska P
    Can J Gastroenterol Hepatol; 2018; 2018():6095097. PubMed ID: 30402450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
    AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.
    Weidner P; Boettche D; Zimmerer T; Burgermeister E; Teufel A; Ebert MPA; Antoni C
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):281-289. PubMed ID: 30240472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study.
    Adinolfi LE; Petta S; Fracanzani AL; Nevola R; Coppola C; Narciso V; Rinaldi L; Calvaruso V; Pafundi PC; Lombardi R; Staiano L; Di Marco V; Solano A; Marrone A; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A; Sasso FC
    Diabetes Obes Metab; 2020 Dec; 22(12):2408-2416. PubMed ID: 32761721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of chronic kidney disease in young adults with impaired glucose tolerance/impaired fasting glucose: a retrospective cohort study using electronic primary care records.
    Jadhakhan F; Marshall T; Ryan R; Gill P
    BMC Nephrol; 2018 Feb; 19(1):42. PubMed ID: 29482513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection.
    Huang JF; Yu ML; Dai CY; Hsieh MY; Hwang SJ; Hsiao PJ; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Shin SJ; Chang WY; Chuang WL
    Am J Gastroenterol; 2008 Aug; 103(8):1933-40. PubMed ID: 18637090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
    Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
    Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4.
    Zied HY; Abo Alnasr NM; El-Bendary AS; Abd-Elsalam S; Hagag RY
    Diabetes Metab Syndr; 2020; 14(4):679-682. PubMed ID: 32438332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses.
    Anty R; Gelsi E; Giudicelli J; Mariné-Barjoan E; Gual P; Benzaken S; Saint-Paul MC; Sadoul JL; Huet PM; Tran A
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):671-7. PubMed ID: 17625437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of type II diabetes mellitus in population of Krakow].
    Szurkowska M; Szybiński Z; Nazim A; Szafraniec K; Jedrychowski W
    Pol Arch Med Wewn; 2001 Sep; 106(3):771-9. PubMed ID: 11928585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1.
    Salomone F; Catania M; Montineri A; Bertino G; Godos J; Rizzo L; Magrì G; Li Volti G
    Liver Int; 2018 Jul; 38(7):1206-1211. PubMed ID: 29265719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.